Misplaced Pages

Moxaverine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Moxaverine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 1-Benzyl-3-ethyl-6,7-dimethoxyisoquinoline
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.031.003 Edit this at Wikidata
Chemical and physical data
FormulaC20H21NO2
Molar mass307.393 g·mol
3D model (JSmol)
SMILES
  • CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3
InChI
  • InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3
  • Key:MYCMTMIGRXJNSO-UHFFFAOYSA-N
  (what is this?)  (verify)

Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor, and on its influence on the rheological properties of red blood cells.

Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion. The ocular efficacy of moxaverine has been explored in the clinic.

References

  1. Mannhold R (December 1988). "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittel-Forschung. 38 (12): 1806–8. PMID 2854468.
  2. Schmid-Schönbein H, Schröder S, Grebe R, Artmann G, Eschweiler H, Teitel P (May 1988). "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittel-Forschung. 38 (5): 710–6. PMID 3415714.
  3. Pemp B, Garhofer G, Lasta M, Schmidl D, Wolzt M, Schmetterer L (March 2012). "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmologica. 90 (2): 139–45. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253. S2CID 3269602.
  4. Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov
Drugs for functional gastrointestinal disorders (A03)
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
Phosphodiesterase inhibitors
PDE1
PDE2
PDE3
PDE4
PDE5
PDE7
PDE9
PDE10
PDE11BC11-38
Non-selective
Unsorted
See also: Receptor/signaling modulators
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: